Erowid References Database
Gilhooly TC, Daly AK.
“CYP2D6 deficiency, a factor in ecstasy related deaths?”.
Br J Clin Pharmacol. 2002 Jul 08;54(1):69-70.
No abstract. Summary: The authors performed an analysis of post-mortem tissue from ecstasy related fatalities for CYP2D6 gene variants. No evidence of a higher percentage of poor metabolizers in the sample of ecstasy-related fatalities.
Ecstasy related deaths are rare and complex events, which have so far defied adequate explanation. Of the 14 post mortem samples that could be genotyped in this study, none was genotyped as PM of CYP2D6 and, therefore, would not be expected to show deficient metabolism of MDMA. Our study is small which limits its power and fails to demonstrate statistical significance but our findings do support those of O’Donohoe that poor metabolizers of CYP2D6 are not at greater risk of ecstasy-related death. There appear to be other metabolic mechanisms which compensate for the poor metabolism of these drugs by CYP2D6 .
[ Cite HTML